Department of Dermatology, Northern Border University, Arar, Saudi Arabia.
J Pak Med Assoc. 2024 Jul;74(7):1361-1363. doi: 10.47391/JPMA.9817.
Adalimumab is a human monoclonal antibody that selectively targets tumour necrosis factor-alpha (TNF- α), a cytokine involved in the pathogenesis of various inflammatory and autoimmune disorders. Adalimumab has been approved worldwide for the treatment of several chronic immune-mediated diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. One of the adverse reactions caused by Adalimumab is psoriasis. This study reports the case of a 37-year-old male with palmoplantar psoriasis triggered by adalimumab for treatment of Crohn's disease. This eruption resisted complete clearance with various potent corticosteroids. The patient was referred back to the treating rheumatologist to possibly change adalimumab to another type of therapy.
阿达木单抗是一种人源化单克隆抗体，能选择性地靶向肿瘤坏死因子-α（TNF-α），该细胞因子与多种炎症性和自身免疫性疾病的发病机制有关。阿达木单抗已在全球范围内获准用于治疗多种慢性免疫介导性疾病，包括类风湿关节炎、银屑病、银屑病关节炎、强直性脊柱炎、克罗恩病、溃疡性结肠炎和幼年特发性关节炎。阿达木单抗引起的不良反应之一是银屑病。本研究报告了一例 37 岁男性患者，因使用阿达木单抗治疗克罗恩病而引发掌跖银屑病。尽管使用了各种强效皮质类固醇，但该患者的皮疹仍未完全消退。患者被转介给治疗风湿科医生，以考虑将阿达木单抗更换为另一种治疗方法。
